The Pharma Data

JUNE 12, 2025

Expanding Targeted Protein Degradation in Hematologic Malignancies Targeted protein degradation is a powerful therapeutic approach designed to destroy disease-driving proteins within cells, thereby inhibiting their ability to contribute to disease progression.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Treatment Disease 40

Drug Target Review

JULY 21, 2025

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. This protective barrier prevents more than 98 percent of small-molecule drugs and all macromolecular therapeutics 3 from accessing the brain.

Drug Development 64

Drug Development Small Molecule Drugs Therapies 64

BioPharma Drive: Drug Pricing

JULY 8, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Drugmakers are working to coopt this process with targeted therapies. You can unsubscribe at anytime.

Targeted Protein Degradation 144

Targeted Protein Degradation Small Molecule Disease Therapies 144

Drug Target Review

JULY 23, 2024

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Source link.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

SEPTEMBER 15, 2020

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Science Small Molecule 52